Sunlight Medical Markets
First Multi-Site Bone Sonometer in the United States
Somerset, N.J., U.S.A. (August 1, 2001) - Sunlight Medical Inc. has launched the first multi-site bone sonometer in the United States. Sunlight Omnisense™ 7000S is the only bone sonometer on the market that can test bone strength at more than one skeletal site, making it an ideal solution for osteoporosis management in primary care. Since its launch in the United States, Omnisense has captured a leading share of the US primary care osteoporosis management market.
Omnisense has been clinically proven to accurately predict fracture risk and diagnose osteoporosis, with a short, user-friendly, radiation-free test in the doctor's office. The device is the only radiation-free multi-site device for osteoporosis management on the market that is designed to fit the needs of the office-based physician.
Multi-site assessment enhances Omnisense's diagnostic abilities. "The potential of the Omnisense 7000S to perform multi-site measurements greatly expands the clinical utility of quantitative ultrasound," said Harry K. Genant, M.D., executive director of the Osteoporosis and Arthritis Group at the University of California, San Francisco. "By measuring at several sites - such as the non-weight-bearing distal radius (forearm) and the weight-bearing metatarsal (foot) - the physician obtains improved confidence for the prediction of fracture risk in patients with suspected osteoporosis." Dr. Irit Yaniv, vice president and medical director of Sunlight, added, "Multi-site measurement enables the physician to better monitor changes in the bone. Because different sites reflect treatment at different rates, physicians can measure at more than one site to monitor the effectiveness of treatment for osteoporosis."
"The Omnisense multi-site device, introduced in Europe and East Asia in 1998, has already become the market leader in these markets in osteoporosis management in primary care," declared Markus Maritz, president of Sunlight Medical, Inc. "With increased awareness of the serious consequences of the disease," he added, "we expect that the need for assessment and diagnosis at primary care locations will grow in the coming years."
Sunlight expects multi-site measurement to provide additional momentum to its sales in the United States market.